TY - JOUR
T1 - Antiplatelet effect of differentially charged PEGylated lipid-polymer nanoparticles
AU - Fuentes, Eduardo
AU - Yameen, Basit
AU - Bong, Soung Jae
AU - Salvador-Morales, Carolina
AU - Palomo, Ivan
AU - Vilos, Cristian
N1 - Funding Information:
C Vilos acknowledges support from FONDECYT Regular Grant No.1161438, UNAB Regular Grant DI-695-15/R, MECESUP PMI-UAB1301, and the Basal Program for Centers of Excellence, Grant FB0807 CEDENNA, and CONICYT. E Fuentes acknowledges support from FONDECYT Initiation Grant No.11140142, and the Interdisciplinary Excellence Research Program on Healthy Aging (PIEI?ES) from University of Talca.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - PEGylated nanoparticles have been extensively investigated in different platforms for drug delivery. However, the physiological effects related to platelet activation, and the potential procoagulant activity which could lead to thrombosis and further cardiovascular diseases have not been widely examined. In this work, we studied the effect of differentially charged PEGylated lipid-polymer nanoparticles in the human platelet aggregation and activation by light transmission aggregometry and flow cytometry. PEGylated nanoparticles inhibited the platelet aggregation with a dose dependency (350, 700, and 1400 μg/mL) in both ADP- and collagen-induced platelet aggregation, and P-selectin expression. Charged nanoparticles (anionic and cationic) presented higher inhibitions of the platelet aggregation compared to neutral nanoparticles, and particularly the cationic particles generated a slightly higher effect. The obtained results demonstrated the safety of the differentially charged PEGylated lipid-polymer nanoparticles, and their ability to inhibit the aggregation and activation of human platelets stimulated by two classic platelet activators.
AB - PEGylated nanoparticles have been extensively investigated in different platforms for drug delivery. However, the physiological effects related to platelet activation, and the potential procoagulant activity which could lead to thrombosis and further cardiovascular diseases have not been widely examined. In this work, we studied the effect of differentially charged PEGylated lipid-polymer nanoparticles in the human platelet aggregation and activation by light transmission aggregometry and flow cytometry. PEGylated nanoparticles inhibited the platelet aggregation with a dose dependency (350, 700, and 1400 μg/mL) in both ADP- and collagen-induced platelet aggregation, and P-selectin expression. Charged nanoparticles (anionic and cationic) presented higher inhibitions of the platelet aggregation compared to neutral nanoparticles, and particularly the cationic particles generated a slightly higher effect. The obtained results demonstrated the safety of the differentially charged PEGylated lipid-polymer nanoparticles, and their ability to inhibit the aggregation and activation of human platelets stimulated by two classic platelet activators.
KW - Charged nanoparticle
KW - Lipid polymer
KW - PEGylated nanoparticle
KW - Platelet
UR - http://www.scopus.com/inward/record.url?scp=85013459668&partnerID=8YFLogxK
U2 - 10.1016/j.nano.2016.10.010
DO - 10.1016/j.nano.2016.10.010
M3 - Article
AN - SCOPUS:85013459668
SN - 1549-9634
VL - 13
SP - 1089
EP - 1094
JO - Nanomedicine: Nanotechnology, Biology, and Medicine
JF - Nanomedicine: Nanotechnology, Biology, and Medicine
IS - 3
ER -
